Tesamorelin
TH9507
Tesamorelin is the one GHRH analog that made it all the way to FDA approval — a growth-hormone-releasing peptide specifically shown to burn <b>visceral</b> (deep belly) fat. Marketed as Egrifta, it's the gold-standard example of a GH-axis peptide with real Phase III human data. This guide covers how tesamorelin works, what the trials showed, its approved use, dosing, safety and status.
Tesamorelin quick facts
| Reported research dosing | 0.5mg-2mg |
| Route | Subq |
| Cycle length | 3-6 Months |
| Frequency | 1x Daily AM/PM · 5 On 2 Off or Daily |
| Half-life | ~26–38 min |
| Forms | Injectable |
| Evidence level | FDA-approved (visceral/HIV-lipo); human trials |
The most clinically-backed GHRH for visceral fat. Real data, not just bro-lore.
How tesamorelin works
Tesamorelin is a stabilized GHRH (1-44) analog — the full GHRH molecule with an N-terminal modification that resists enzymatic breakdown. It binds pituitary GHRH receptors and drives a pulse of your own growth hormone. The reason it targets belly fat specifically: visceral fat has a higher density of GH receptors and a higher lipolytic rate than subcutaneous fat, so a GH pulse lands disproportionately on the deep abdominal depot.
What the research shows
This is tesamorelin's standout: real Phase III human data. In a pooled analysis of 806 participants across two trials, tesamorelin reduced visceral adipose tissue by about 15.4% versus placebo at 26 weeks — while largely sparing subcutaneous fat. That selectivity for deep abdominal fat is what makes it clinically distinctive and why it's studied off-label for visceral-fat and metabolic goals beyond its approved indication.
Approved use & brand names
Tesamorelin (brand Egrifta, and newer Egrifta SV / Egrifta WR) is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy — the only GHRH-analog drug ever approved (2010). Whether it's appropriate for a person is a decision for a licensed prescriber.
Dosing (as approved / studied)
Approved dosing has been a daily subcutaneous injection: original Egrifta at 2 mg/day, Egrifta SV at 1.4 mg/day. In 2025 the FDA approved a new F8 formulation (Egrifta WR) at 1.28 mg with the convenience of weekly reconstitution instead of daily, improving adherence. Actual dosing must be set and supervised by a prescriber; these figures summarize the approved schedules for education only.
Safety & side effects
Common effects include injection-site reactions, joint pain, and fluid retention. As a GH-axis therapy it raises GH and IGF-1, so IGF-1 is monitored and it carries the class caution around IGF-1 and cancer risk; it's contraindicated in active malignancy. This is a prescription medication for good reason — medically supervised, with monitoring.
Tesamorelin vs the other GH options
Tesamorelin is the strongest, best-evidenced GHRH — FDA-approved and specifically visceral-fat selective. Sermorelin is the gentler GHRH; the CJC-1295 + Ipamorelin stack adds a GHRP for a bigger pulse; MK-677 is the oral secretagogue. Tesamorelin stands out for actually having human outcome data behind it.
Legal & regulatory status
Tesamorelin is a prescription medication, FDA-approved as Egrifta for HIV-associated lipodystrophy. Anything sold as tesamorelin outside a legitimate prescription is unapproved, and GH secretagogues are banned in competitive sport under WADA. This page is educational, not a recommendation to obtain or use it.
Where to get Tesamorelin
Buy Tesamorelin at AminoWell USA →Tesamorelin reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Tesamorelin
Graded by what exists behind each claim.
✅ Clinically validated
- The strongest human evidence of any growth-hormone secretagogue here. FDA-approved as Egrifta for HIV-associated lipodystrophy on the back of two phase-3 trials, where it cut visceral adipose tissue by roughly 15–18% over 26 weeks against placebo.
- A separate NIH trial in non-HIV adults with NAFLD showed reduced liver fat, which matters because it is the one result that generalizes beyond the licensed population most readers do not belong to.
📊 Correlative data
- Off-label use for visceral fat in metabolically healthy adults is common and unstudied. The approval population had a specific disease driving a specific fat distribution, and how much of the effect survives in someone without it is genuinely unknown — the mechanism should carry over, the effect size probably does not.
🧪 Theoretical / extrapolated
- A GHRH analog: it acts one step upstream of growth hormone, on the pituitary, so release stays pulsatile and under normal feedback control. That is the mechanistic argument for it over exogenous HGH, and it predicts the two things reliably observed — visceral fat responds first, and IGF-1 rises modestly rather than dramatically.
- The same feedback loop predicts the downside: it cannot exceed what your pituitary can produce, so it does far less in someone whose GH axis is already failing than in someone whose axis works.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Tesamorelin actually does
Tesamorelin is the only compound in this class with an FDA approval, and the approval is for one specific fat depot in one specific population. Its label states the indication in as many words: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and explicitly not for general weight management Egrifta WR label 2025.
The receptor, and why it is the right one. The label describes tesamorelin as a growth hormone-releasing factor analog that binds and stimulates human GRF receptors, causing the pituitary to release endogenous growth hormone Egrifta WR label 2025. The GHRH receptor is a class B GPCR on the somatotroph coupled to Gs: cAMP, protein kinase A, and transcription of the growth hormone gene together with acute release. Because the hormone comes out of the person's own pituitary, it comes out in pulses and it remains under the two brakes that exogenous growth hormone bypasses — hypothalamic somatostatin and hepatic IGF-1 feedback. That is the entire pharmacological argument for a GHRH analog over injected growth hormone Yuen 2024.
The comparison is worth making concrete, because the alternative has its own label. Recombinant somatropin is growth hormone itself, delivered directly and bypassing both brakes Norditropin label. A GHRH analog cannot exceed what the somatotroph is willing to release; injected growth hormone can, and the difference shows up as a ceiling on IGF-1 rather than as a difference in receptor. That ceiling is also why the performance claims made for growth hormone have survived so poorly under measurement Ho 2019, and a secretagogue route inherits that skepticism rather than escaping it.
The structural problem it was built to solve. Native GHRH is destroyed within minutes by dipeptidyl peptidase-4, which clips the N-terminal dipeptide off and inactivates it. Tesamorelin carries a hydrophobic acyl modification on the N-terminus that protects that site. The protection is real and partial: the current EGRIFTA WR label reports a half-life of about 11 minutes and subcutaneous bioavailability of less than 4%, with a median time to peak of 0.15 hours Egrifta WR label 2025. Eleven minutes and under 4% bioavailability is a startling pair of numbers for a drug that works, and it is the clearest demonstration in this Vault that a peptide does not have to persist to have an effect — it has to arrive at the pituitary as a pulse. The Vault card's 26 to 38 minute figure comes from earlier formulation and population data; both numbers are in the record and they describe different products.
Why visceral fat specifically, which is the part nobody explains. Growth hormone is lipolytic, and visceral adipose tissue expresses more growth hormone receptor and is more lipolytically responsive than subcutaneous fat. It also drains into the portal vein, so a lipolytic signal there delivers free fatty acids straight to the liver. That anatomy is why the approved endpoint is a visceral depot rather than body weight, and why the liver is the organ where the next set of questions live Doycheva 2022.
Cell, rodent, human — and where it stops
Step one, receptor pharmacology and the growth hormone axis: settled, and recently re-reviewed Yuen 2024.
Step two, humans, randomized, and approved on the strength of it. The registrational program ran 26-week randomized trials with a visceral adipose tissue endpoint measured by imaging, and the label records both the effect and the cost: injection site reactions in 17% against 6% on placebo, arthralgia 13% against 11% Egrifta WR label 2025. An imaging endpoint in a randomized trial that produced a license is the highest grade of evidence anything in this Vault has.
Step three, pooled. A meta-analysis of randomized controlled trials examined body composition, hepatic fat, metabolic and safety outcomes of tesamorelin in HIV-associated lipodystrophy Badran 2026. Hepatic fat sits in that title alongside body composition, which is the mechanistic point: the drug is acting on a portal-drained depot, so the liver is downstream of the effect.
Step four, the extrapolation that follows, clearly labeled as extrapolation. Growth hormone deficiency and fatty liver disease are linked, and the link is underrecognized Doycheva 2022. If the mechanism is visceral lipolysis with a hepatic consequence, then a GHRH analog should help hepatic steatosis in people without HIV — different population, same anatomy. That is a hypothesis with a coherent mechanism and no approval behind it, and stating it as a hypothesis is the honest way to carry it.
Where the chain breaks. (1) Every registrational trial was in people with HIV-associated lipodystrophy — a specific adipose pathology driven partly by antiretroviral exposure, not ordinary central adiposity. (2) The trials are 26 weeks. (3) The label states plainly that the effect is not maintained after discontinuation of therapy, so this is a treatment rather than a correction. (4) The label carries an increased-risk-of-neoplasm warning Egrifta WR label 2025, which is the boundary condition on every extrapolation on this page.
What would have to be true, and how you would know it was not
Three predictions. The first is the one the label itself requires, and that is unusual enough to be worth saying out loud.
1. IGF-1 is not optional here. It is a labeled monitoring requirement. The label lists Elevated IGF-1 Levels as a warning and instructs that IGF-1 be monitored during therapy Egrifta WR label 2025. It is also the read-out that proves the drug is working: a GHRH analog that does not raise IGF-1 has not reached the pituitary. Measure IGF-1 at baseline and at 3 months. A flat IGF-1 means the drug is not being delivered; a very high IGF-1 means the dose is above what the feedback loop is absorbing, and the label treats that as a reason to reassess rather than a sign of success.
2. Glucose is the labeled cost and it has to be measured before and during. The label carries Glucose Intolerance or Diabetes Mellitus as a warning and calls for glucose status to be evaluated before and during therapy Egrifta WR label 2025. Growth hormone antagonizes insulin action at the liver and in muscle, so this is direct pharmacology. HbA1c and fasting insulin at baseline and 12 weeks, with a CMP for fasting glucose. If glucose markers deteriorate while visceral fat falls, the drug has traded one cardiometabolic risk factor for another, and only measuring both makes that visible.
3. The efficacy prediction is anatomical and a scale cannot see it. The approved endpoint is a visceral depot measured by imaging, not body weight Egrifta WR label 2025. So: waist circumference at a fixed landmark at baseline and 6 months, and if available a DEXA or CT-derived visceral fat measure. ALT, AST and GGT on the same CMP as the hepatic read-out Badran 2026 Doycheva 2022. Body weight can be completely unchanged while the intended effect has occurred, and judging this drug on a scale is judging it on the wrong instrument.
What nobody has tested yet
Four experiments nobody has run.
Nobody has run a registrational trial outside HIV-associated lipodystrophy. The mechanism gives no reason to think visceral adipose growth hormone receptors behave differently in somebody without HIV, and that is exactly why the trial is needed rather than assumed. Until it exists, every use outside the label is an extrapolation from one adipose pathology to another.
Nobody has tested it head-to-head against a GLP-1 receptor agonist on a visceral endpoint. Both reduce visceral fat by entirely different routes. A randomized comparison with imaged visceral adipose tissue and hepatic fat as co-primary endpoints would be the most decision-relevant trial in this whole area, and neither sponsor has an incentive to run it.
Nobody has resolved the half-life discrepancy in public. The current label reports about 11 minutes Egrifta WR label 2025; older figures in circulation are two to three times that. Whether the difference is formulation, population, assay or all three has never been laid out in one place, and it matters because dosing intervals were reasoned from the older number.
Nobody has measured what happens after two years. The label says the effect is not maintained after discontinuation Egrifta WR label 2025, and the trials are 26 weeks. Whether continuous multi-year GHRH agonism is metabolically stable — particularly given the glucose warning and the neoplasm warning on the same page — is unmeasured, and it is the question every long-term user is already living inside.
Tesamorelin — its own safety story, not its class's
Tesamorelin has an FDA-approved label, which makes this the rare case where the risks are written down by a regulator rather than inferred. Here is what that label says Egrifta WR label 2025.
Increased risk of neoplasms is a labeled warning. Growth hormone and IGF-1 are mitogenic. The label carries the warning explicitly, and it is the reason an active malignancy is a contraindication and a personal history of one is a specialist conversation. This is the boundary condition on the entire compound and it is not a theoretical concern invented by this page.
Elevated IGF-1 levels, with monitoring required. The label instructs that IGF-1 be monitored during therapy. That is a labeled obligation, not a suggestion, and it is in the predictions section above because it is also the measurement that proves the drug is working.
Glucose intolerance or diabetes mellitus, with evaluation before and during. Growth hormone opposes insulin action. In somebody already insulin resistant — which describes a large share of the people interested in a visceral fat drug — this is the warning most likely to matter.
Fluid retention, injection site reactions, and hypersensitivity. Injection site erythema and pruritus occurred in 17% against 6% on placebo in the 26-week trials, and arthralgia in 13% against 11%. The label notes that fluid retention and edema are transient or resolve on discontinuation, and instructs rotation of injection sites.
Increased mortality in acute critical illness is on the label as its own warning. It comes from the growth hormone literature in intensive care and it is the reason this class is stopped, not continued, in somebody who becomes acutely unwell.
What this page will not do. Recommend a dose or extend the indication. It is an approved drug for reduction of excess abdominal fat in HIV-associated lipodystrophy Egrifta WR label 2025, with a neoplasm warning, a glucose warning and a labeled IGF-1 monitoring requirement — and each of those three is a reason the decision belongs with a prescriber.
Sources read for this page
- U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information, including the IGF-1 monitoring requirement and the neoplasm warning. DailyMed, U.S. National Library of Medicine; label revised 2025
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research and Clinical Practice 2026 · PMID 41545261
- Yuen KCJ, et al. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Frontiers in Endocrinology 2024 · PMID 39665021
- Doycheva I, et al. Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. Hepatology Communications 2022 · PMID 35765700
Tesamorelin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analog (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogs together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Fasted — and pre-bed is the best of the windows
Food is the problem here, and specifically carbohydrate and fat. Both trigger somatostatin release, and somatostatin is the brake on growth hormone — eating before the injection pharmacologically cancels it. Two clear hours either side.
Pre-bed is the strongest window because the largest natural GH pulse happens in the first hours of deep sleep, so you are stacking with it rather than asking the pituitary for something it is not primed for. Fasted pre-training is the second-best, for the same reason in a different rhythm.
From half-life and route, not a dosing trial.
Tesamorelin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Tesamorelin moves on your bloodwork
Expected direction, not a measured one.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Tesamorelin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The dosing target — this is the only GH peptide with real trial data |
| Fasting Insulin | Insulin sensitivity worsens across this whole class |
| HbA1c (Hemoglobin A1c) | Slower confirmation |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Visceral fat reduction should show here if it's working |
The “Running GH Peptides or MK-677” panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 103 markers A–Z
Tesamorelin — frequently asked questions
What is tesamorelin?
Tesamorelin is a stabilized GHRH (1-44) analog that stimulates your pituitary to release growth hormone. It's FDA-approved (Egrifta) to reduce visceral abdominal fat in adults with HIV and lipodystrophy — the only approved GHRH-analog drug.
How does tesamorelin burn belly fat?
It triggers a GH pulse, and visceral (deep abdominal) fat has more GH receptors and a higher lipolytic rate than subcutaneous fat — so the GH effect lands disproportionately on belly fat, largely sparing fat just under the skin.
How much visceral fat does tesamorelin reduce?
In pooled Phase III data (806 participants), tesamorelin reduced visceral adipose tissue by about 15.4% versus placebo at 26 weeks, while largely sparing subcutaneous fat. Individual results vary.
How is tesamorelin dosed?
Approved dosing has been daily subcutaneous (2 mg Egrifta; 1.4 mg Egrifta SV). A 2025 weekly-reconstitution formulation (Egrifta WR, 1.28 mg) improved convenience. Dosing must be prescriber-supervised; this is educational only.
Is tesamorelin FDA-approved?
Yes — as Egrifta / Egrifta SV / Egrifta WR, for excess abdominal fat in adults with HIV and lipodystrophy. It's the only FDA-approved GHRH-analog drug.
What are the side effects of tesamorelin?
Commonly injection-site reactions, joint pain and fluid retention. It raises IGF-1, so IGF-1 is monitored and it carries the class cancer caution; it's contraindicated in active malignancy.
References & further reading
- FDA approves F8 (Egrifta WR) tesamorelin for HIV lipodystrophy (2025)
- Tesamorelin: complete guide to the FDA-approved GHRH analog
Tesamorelin inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What Tesamorelin is used for
Tesamorelin appears under 2 goals in the goal router.
Related GH & Growth compounds
Where this goes next
Tesamorelin is the lean-mass arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.